Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations

Blood

Volumn 116, Issue 26, 2010, Pages 5832-5837

  Pecci, Alessandro ^a   Gresele, Paolo ^b   Klersy, Catherine ^a   Savoia, Anna ^c   Noris, Patrizia ^a   Fierro, Tiziana ^b   Bozzi, Valeria ^a   Mezzasoma, Anna Maria ^b   Melazzini, Federica ^a   Balduini, Carlo L ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG;

ADULT; ARTICLE; BLEEDING; CATARACT; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE; GENE MUTATION; HUMAN; MALE; MULTICENTER STUDY; MYH9 GENE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; XEROSTOMIA;

EID: 78650669297     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-304725     Document Type: Article

References (22)

1. Nurden AT, Nurden P. Inherited thrombocytopenias. Haematologica. 2007;92(9):1158-1164.
2. Seri M, Pecci A, Di Bari F, et al. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore). 2003;82(3):203-215.
3. Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost. 2009;35(2):189-203.
4. Pecci A, Panza E, Pujol-Moix N, et al. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat. 2008;29(3):409-417.
5. Geddis AE. Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii. Hematol Oncol Clin North Am. 2009;23(2):321-331.
6. Locatelli F, Rossi G, Balduini C. Hematopoietic stem-cell transplantation for the Bernard-Soulier syndrome. Ann Intern Med. 2003;138(1):79.
7. Notarangelo LD, Miao CH, Ochs HD. Wiskott-Aldrich syndrome. Curr Opin Hematol. 2008;15(1):30-36.
8. Balduini CL, Noris P, Belletti S. Spedini P. Gamba G. In vitro and in vivo effects of desmopressin on platelet function. Haematologica. 1999;84(10):891-896.
9. Lee DH, Blajchman MA. Novel treatment modalities: new platelet preparations and substitutes. Br J Haematol. 2001;114(3):496-505.
10. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237- 2247.
11. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9664):641-648.
12. McHutchison JG, Dusheiko G, Shiffman ML, et al. TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357(22):2227-2236.
13. Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lowerrisk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010;28(3):437-444.
14. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med. 2006;355(16):1672-1681.
15. Bussel JB, Kuter DJ, Pullarkat V. Lyons RM. Guo M. Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161-2171.
16. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395-403.
17. Pecci A, Malara A, Badalucco S, et al. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation. Thromb Haemost. 2009;102(1):90-96.
18. Noris P, Klersy C, Zecca M, et al. Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. J Thromb Haemost. 2009;7(12):2131-2136.
19. Seri M, Cusano R, Gangarossa S, et al. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. Nat Genet. 2000;26(1):103-105.
20. Cuker A, Chiang EY, Cines DB. Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia. Curr Drug Saf. 2010;5(2):171-181.
21. Noris P, Spedini P, Belletti S. Magrini U. Balduini CL. Thrombocytopenia. giant platelets. and leukocyte inclusion bodies (May-Hegglin anomaly): clinical and laboratory findings. Am J Med. 1998;104(4):355-360.
22. Canobbio I, Noris P, Pecci A. Balduini A. Balduini CL. Torti M. Altered cytoskeleton organization in platelets from patients with MYH9-related disease. J Thromb Haemost. 2005;3(5):1026-1035.